# EDGAR Filing Document

**Accession Number:** 0001677077
**File Stem:** 0001214659-25-011356
**Filing Date:** 2025-8
**Character Count:** 8864
**Document Hash:** 198583789a11f6e817db0490fcc510dd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001214659-25-011356.hdr.sgml**: 20250801

**ACCESSION NUMBER**: 0001214659-25-011356

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250730

**FILED AS OF DATE**: 20250801

**DATE AS OF CHANGE**: 20250801

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** AULT MILTON C III
- **CENTRAL INDEX KEY:** 0001212502

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40483
- **FILM NUMBER:** 251176603

**MAIL ADDRESS:**
- **STREET 1:** 11411 SOUTHERN HIGHLANDS PARKWAY
- **STREET 2:** SUITE 240
- **CITY:** LAS VEGAS
- **STATE:** NV
- **ZIP:** 89141
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Alzamend Neuro, Inc.
- **CENTRAL INDEX KEY:** 0001677077
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 811822909
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0430

**BUSINESS ADDRESS:**
- **STREET 1:** 3500 LENOX RD. NE
- **STREET 2:** SUITE 1500
- **CITY:** ATLANTA
- **STATE:** GA
- **ZIP:** 30326
- **BUSINESS PHONE:** 844-722-6333

**MAIL ADDRESS:**
- **STREET 1:** 3500 LENOX RD. NE
- **STREET 2:** SUITE 1500
- **CITY:** ATLANTA
- **STATE:** GA
- **ZIP:** 30326

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>AULT MILTON C III<br><sub>(Last) (First) (Middle)</sub><br>11411 SOUTHERN HIGHLANDS PARKWAY<br>SUITE 190<br><sub>(Street)</sub><br>LAS VEGAS, NV 89141<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-07-30 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Alzamend Neuro, Inc. [ ALZN ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-07-30 |  | C |  | 100000<sup>(1)</sup> | A | $2.32 | 137709 | I | By Ault Lending, LLC<sup>(2)</sup> |
| Common Stock | 2025-07-30 |  | S |  | 29449 | D | 2.5122<sup>(3)</sup> | 108260 | I | By Ault Lending, LLC<sup>(2)</sup> |
| Common Stock | 2025-07-31 |  | S |  | 100000 | D | 2.2155<sup>(4)</sup> | 8260 | I | By Ault Lending, LLC<sup>(2)</sup> |
| Common Stock |  |  |  |  |  |  |  | 1843 | D |  |
| Common Stock |  |  |  |  |  |  |  | 11068 | I | By Ault Life Sciences, Inc.<sup>(5)</sup> |
| Common Stock |  |  |  |  |  |  |  | 61 | I | By Ault Life Sciences Fund, LLC<sup>(6)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Series B Convertible Preferred Stock | 2.32<sup>(7)</sup> | 2025-07-30 |  | C |  |  | 232 | 2024-01-31 | <sup>(8)</sup> | Common Stock | 100000 | $1000 | 1535.2447 | I | By Ault Lending, LLC<sup>(2)</sup> |
| Common Stock Purchase Warrants | $108.00 |  |  |  |  |  |  | 2024-08-01 | 2029-08-01 | Common Stock | 13556 |  | 13556 | I | By Ault Lending, LLC<sup>(2)</sup> |
| Common Stock Purchase Warrants | $108.00 |  |  |  |  |  |  | 2024-09-27 | 2029-09-27 | Common Stock | 8667 |  | 8667 | I | By Ault Lending, LLC<sup>(2)</sup> |
| Common Stock Purchase Warrants | $108.00 |  |  |  |  |  |  | 2024-10-30 | 2029-10-30 | Common Stock | 1111 |  | 1111 | I | By Ault Lending, LLC<sup>(2)</sup> |
| Common Stock Purchase Warrants | $4050.00 |  |  |  |  |  |  | 2020-08-31 | 2025-08-31 | Common Stock | 12 |  | 12 | I | By Hyperscale Data, Inc.<sup>(9)</sup> |

---

### Footnotes:

(1) Represents shares of common stock received upon conversion of Series B convertible preferred stock ("Series B Preferred").

(2) Ault Lending, LLC ("Ault Lending"), is a wholly-owned subsidiary of Hyperscale Data, Inc. ("HSD"). Mr. Ault, the Executive Chairman of HSD, is deemed to have voting and investment power with respect to the securities held of record by Ault Lending.

(3) The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sale price of $2.5122. The range of sales prices on the transaction date was $2.4047 to $2.6367 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.

(4) The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sale price of $2.2155. The range of sales prices on the transaction date was $2.1628 to $2.2511 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.

(5) Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences, Inc.

(6) Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences Fund, LLC.

(7) The Conversion Price of the Series B Preferred is subject to adjustment as set forth in that certain of Designation of Preferences, Rights and Limitations of the Series B Convertible Voting Preferred Stock.

(8) The shares of Series B Preferred have no expiration date.

(9) Mr. Ault, the Executive Chairman of HSD, is deemed to have voting and investment power with respect to the securities held of record by HSD.

**Signature:** /s/ Milton C. Ault, III  
**Date:** 2025-08-01

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**